Oxalamido-substituted tricyclic inhibitors of hepatitis b virus

A compound of general formula (I):

• wherein:
• Cy is aryl or heteroaryl;
• A is C—R3;
• X is O or S;
• Y, Y′, Y″ are each methanediyl;
• Y′″ is absent;
• R1 is H or C1-6 alkyl;
• R2 is selected from H, OH, halogen and C1-6 alkyl;
• R3 is selected from H, C1-6 alkyl, C3-8 cycloalkyl, haloC1-6 alkyl and halogen;
• R5 is H or C1-6 alkyl;
• R6 is selected from H, C1-6 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C1-6 alkylaryl, C1-6 alkylheteroaryl and C1-6 alkyl-C3-8 cycloalkyl wherein each of said C1-6 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C1-6 alkylaryl, C1-6 alkylheteroaryl or C1-6 alkyl-C3-8 cycloalkyl is optionally substituted with one or more substituents each independently selected from:
• OH, halogen, halo-C1-6 alkyl, cyano and NH2;
• each of R7 and R8 are independently selected from:
• hydrogen;
• C1-12 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, NH2, NH(R9), N(R9)2, haloC1-6alkyl, aryl, heteroaryl, 3-7 membered saturated ring and 5-7 membered partially saturated ring, each of said saturated or partially saturated ring optionally containing one or more heteroatoms selected from the group consisting of O, N and S and each of said aryl, heteroaryl, 3-7 membered saturated ring or 5-7 membered partially saturated ring being optionally substituted with one or more substituents each independently selected from:
• OH, halogen, C1-6 alkyl, haloC1-6 alkyl, CN, haloC1-6 alkoxy and C1-6 alkoxy;
• aryl or heteroaryl, each of said aryl or heteroaryl being optionally substituted with one or more substituents each independently selected from:
• OH, halogen, haloC1-6 alkyl, CN, haloC1-6 alkoxy and C1-6 alkoxy;
• and
• a 3-8 membered saturated or partially saturated cyclic or bicyclic ring optionally containing one or more heteroatoms each independently selected from the group consisting of:
• O, S and N, the 3-8 membered saturated or partially saturated cyclic or bicyclic ring being optionally substituted with one, two or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, C1-6 alkyl, hydroxyC1-6 alkyl, C(O)OR9, C(O)R9, halo-C1-6 alkyl, haloC1-6 alkoxy and C1-6 alkoxy;
• or R7 and R8 form together with the nitrogen atom to which they are attached a cyclic amine selected from:
• aziridine, azetidine, pyrrolidine, piperidine, azepane, morpholine, thiomorpholine and piperazine each of said cyclic amine being optionally substituted with one or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, C1-6 alkyl, hydroxyC1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy and C1-6 alkoxy;
• Ra, Rb, Rc and Rd are each independently selected from the group consisting of:
• hydrogen, halogen, CN, C1-6 alkyl, C1-6 alkoxy, haloC1-6 alkyl, haloC1-6 alkoxy, C(O)OR9, C(O)R9, NH2, NH(R9), N(R9)2;
• each R9 is independently selected from C1-6 alkyl, haloC1-6 alkyl, C1-6 alkylaryl, C1-6 alkylheteroaryl and C1-6 alkyl-C3-8cycloalkyl;
• or a pharmaceutically acceptable salt, tautomer, solvate or stereoisomer thereof.